{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T15:26:26Z","timestamp":1788103586901,"version":"build-2803163510"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T00:00:00Z","timestamp":1765843200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T00:00:00Z","timestamp":1767139200000},"content-version":"vor","delay-in-days":15,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-28563-9","type":"journal-article","created":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T19:55:18Z","timestamp":1765914918000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Analysis of anticancer drug associated adverse reactions in depressive patients from vigibase"],"prefix":"10.1038","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7483-2489","authenticated-orcid":false,"given":"Basile","family":"Chretien","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Dolladille","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuki","family":"Nishida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Branko","family":"Aleksic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joachim","family":"Alexandre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Matthieu","family":"L\u2019orphelin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,16]]},"reference":[{"key":"28563_CR1","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s13613-019-0487-x","volume":"9","author":"V Lemiale","year":"2019","unstructured":"Lemiale, V. et al. Severe toxicity from checkpoint protein inhibitors: what intensive care physicians need to know? Ann. Intensive Care. 9, 25 (2019).","journal-title":"Ann. Intensive Care"},{"key":"28563_CR2","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1186\/s12885-021-07946-x","volume":"21","author":"R Du","year":"2021","unstructured":"Du, R. et al. Adverse reactions of targeted therapy in cancer patients: a retrospective study of hospital medical data in China. BMC Cancer. 21, 206 (2021).","journal-title":"BMC Cancer"},{"key":"28563_CR3","doi-asserted-by":"publisher","first-page":"4700","DOI":"10.3390\/curroncol30050355","volume":"30","author":"CA Mallio","year":"2023","unstructured":"Mallio, C. A. et al. Adverse effects of Immune-Checkpoint inhibitors: A comprehensive Imaging-Oriented review. Curr. Oncol. 30, 4700\u20134723 (2023).","journal-title":"Curr. Oncol."},{"key":"28563_CR4","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1038\/s41416-018-0037-6","volume":"118","author":"JW Kim","year":"2018","unstructured":"Kim, J. W. et al. Predicting cumulative incidence of adverse events in older patients with cancer undergoing first-line palliative chemotherapy: Korean cancer study group (KCSG) multicentre prospective study. Br. J. Cancer. 118, 1169\u20131175 (2018).","journal-title":"Br. J. Cancer"},{"key":"28563_CR5","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1182\/blood.2024024442","volume":"144","author":"RP Taylor","year":"2024","unstructured":"Taylor, R. P. & Lindorfer, M. A. Antibody-drug conjugate adverse effects can be understood and addressed based on immune complex clearance mechanisms. Blood 144, 137\u2013144 (2024).","journal-title":"Blood"},{"key":"28563_CR6","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.ejca.2015.11.016","volume":"54","author":"JM Michot","year":"2016","unstructured":"Michot, J. M. et al. Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur. J. Cancer. 54, 139\u2013148 (2016).","journal-title":"Eur. J. Cancer"},{"key":"28563_CR7","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1158\/1078-0432.CCR-15-1136","volume":"22","author":"M Freeman-Keller","year":"2016","unstructured":"Freeman-Keller, M. et al. Nivolumab in resected and unresectable metastatic melanoma: characteristics of Immune-Related adverse events and association with outcomes. Clin. Cancer Res. 22, 886\u2013894 (2016).","journal-title":"Clin. Cancer Res."},{"key":"28563_CR8","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1093\/annonc\/mdv383","volume":"26","author":"J Naidoo","year":"2015","unstructured":"Naidoo, J. et al. Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. Ann. Oncol. 26, 2375\u20132391 (2015).","journal-title":"Ann. Oncol."},{"key":"28563_CR9","doi-asserted-by":"publisher","first-page":"e2239","DOI":"10.1002\/onco.13940","volume":"26","author":"T Xie","year":"2021","unstructured":"Xie, T. et al. The inconsistent and inadequate reporting of Immune-Related adverse events in PD-1\/PD-L1 inhibitors: A systematic review of randomized controlled clinical trials. Oncologist 26, e2239\u2013e2246 (2021).","journal-title":"Oncologist"},{"key":"28563_CR10","doi-asserted-by":"publisher","first-page":"e008591","DOI":"10.1136\/jitc-2023-008591","volume":"12","author":"K Fletcher","year":"2024","unstructured":"Fletcher, K. & Johnson, D. B. Chronic immune-related adverse events arising from immune checkpoint inhibitors: an update. J. Immunother Cancer. 12, e008591 (2024).","journal-title":"J. Immunother Cancer"},{"key":"28563_CR11","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/0885-3924(94)90192-9","volume":"9","author":"MJ Massie","year":"1994","unstructured":"Massie, M. J., Gagnon, P. & Holland, J. C. Depression and suicide in patients with cancer. J. Pain Symptom Manage. 9, 325\u2013340 (1994).","journal-title":"J. Pain Symptom Manage."},{"key":"28563_CR12","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/S1470-2045(11)70002-X","volume":"12","author":"AJ Mitchell","year":"2011","unstructured":"Mitchell, A. J. et al. Prevalence of depression, anxiety, and adjustment disorder in oncological, haematological, and palliative-care settings: a meta-analysis of 94 interview-based studies. Lancet Oncol. 12, 160\u2013174 (2011).","journal-title":"Lancet Oncol."},{"key":"28563_CR13","doi-asserted-by":"publisher","first-page":"k1415","DOI":"10.1136\/bmj.k1415","volume":"361","author":"A Pitman","year":"2018","unstructured":"Pitman, A., Suleman, S., Hyde, N. & Hodgkiss, A. Depression and anxiety in patients with cancer. BMJ 361, k1415 (2018).","journal-title":"BMJ"},{"key":"28563_CR14","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1186\/s13643-022-02107-y","volume":"11","author":"MM Pertl","year":"2022","unstructured":"Pertl, M. M. et al. Effective management of depression among patients with cANCEr (ENHANCE): a protocol for a hybrid systematic review and network meta-analysis of randomised controlled trials of interventions for depressive symptoms. Syst. Reviews. 11, 239 (2022).","journal-title":"Syst. Reviews"},{"key":"28563_CR15","doi-asserted-by":"crossref","unstructured":"Massie, M. J. Prevalence of Depression in Patients With Cancer. JNCI Monographs 57\u201371 (2004). (2004).","DOI":"10.1093\/jncimonographs\/lgh014"},{"key":"28563_CR16","doi-asserted-by":"publisher","unstructured":"Massa, E. et al. The difficult task of diagnosing depression in elderly people with cancer: A systematic review. https:\/\/doi.org\/10.2174\/1745017902117010295","DOI":"10.2174\/1745017902117010295"},{"key":"28563_CR17","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.3892\/ol.2015.2944","volume":"9","author":"HR Smith","year":"2015","unstructured":"Smith, H. R. Depression in cancer patients: Pathogenesis, implications and treatment (Review). Oncol. Lett. 9, 1509\u20131514 (2015).","journal-title":"Oncol. Lett."},{"key":"28563_CR18","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1186\/s12885-019-6181-4","volume":"19","author":"CL Niedzwiedz","year":"2019","unstructured":"Niedzwiedz, C. L., Knifton, L., Robb, K. A., Katikireddi, S. V. & Smith, D. J. Depression and anxiety among people living with and beyond cancer: a growing clinical and research priority. BMC Cancer. 19, 943 (2019).","journal-title":"BMC Cancer"},{"key":"28563_CR19","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1038\/s41380-019-0595-x","volume":"25","author":"YH Wang","year":"2020","unstructured":"Wang, Y. H. et al. Depression and anxiety in relation to cancer incidence and mortality: a systematic review and meta-analysis of cohort studies. Mol. Psychiatry. 25, 1487\u20131499 (2020).","journal-title":"Mol. Psychiatry"},{"key":"28563_CR20","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.jad.2008.04.002","volume":"113","author":"M Lloyd-Williams","year":"2009","unstructured":"Lloyd-Williams, M., Shiels, C., Taylor, F. & Dennis, M. Depression\u2013an independent predictor of early death in patients with advanced cancer. J. Affect. Disord. 113, 127\u2013132 (2009).","journal-title":"J. Affect. Disord"},{"key":"28563_CR21","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1017\/S0033291709992285","volume":"40","author":"M Pinquart","year":"2010","unstructured":"Pinquart, M. & Duberstein, P. R. Depression and cancer mortality: a meta-analysis. Psychol. Med. 40, 1797\u20131810 (2010).","journal-title":"Psychol. Med."},{"key":"28563_CR22","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/S0165-0327(01)00413-X","volume":"72","author":"P Cuijpers","year":"2002","unstructured":"Cuijpers, P. & Smit, F. Excess mortality in depression: a meta-analysis of community studies. J. Affect. Disord. 72, 227\u2013236 (2002).","journal-title":"J. Affect. Disord"},{"key":"28563_CR23","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.4081\/jphr.2021.2247","volume":"10","author":"F Sancassiani","year":"2021","unstructured":"Sancassiani, F. et al. The association between major depressive disorder and premature death risk in hematologic and solid cancer: a longitudinal cohort study. J. Public. Health Res. 10, 2247 (2021).","journal-title":"J. Public. Health Res."},{"key":"28563_CR24","doi-asserted-by":"publisher","first-page":"e0296892","DOI":"10.1371\/journal.pone.0296892","volume":"19","author":"D Ikhile","year":"2024","unstructured":"Ikhile, D., Ford, E., Glass, D., Gremesty, G. & van Marwijk, H. A systematic review of risk factors associated with depression and anxiety in cancer patients. PLOS ONE. 19, e0296892 (2024).","journal-title":"PLOS ONE"},{"key":"28563_CR25","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1136\/bmj.39524.439618.25","volume":"336","author":"TJ Kaptchuk","year":"2008","unstructured":"Kaptchuk, T. J. et al. Components of placebo effect: randomised controlled trial in patients with irritable bowel syndrome. BMJ 336, 999\u20131003 (2008).","journal-title":"BMJ"},{"key":"28563_CR26","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1258\/jrsm.2008.070466","volume":"101","author":"FG Miller","year":"2008","unstructured":"Miller, F. G. & Kaptchuk, T. J. The power of context: reconceptualizing the placebo effect. J. R Soc. Med. 101, 222\u2013225 (2008).","journal-title":"J. R Soc. Med."},{"key":"28563_CR27","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1016\/j.jpain.2016.01.474","volume":"17","author":"M Hermesdorf","year":"2016","unstructured":"Hermesdorf, M. et al. Pain sensitivity in patients with major depression: differential effect of pain sensitivity Measures, somatic Cofactors, and disease characteristics. J. Pain. 17, 606\u2013616 (2016).","journal-title":"J. Pain"},{"key":"28563_CR28","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1111\/jdv.17855","volume":"36","author":"Z Apalla","year":"2022","unstructured":"Apalla, Z. et al. European recommendations for management of immune checkpoint inhibitors-derived dermatologic adverse events. The EADV task force \u2018Dermatology for cancer patients\u2019 position statement. J. Eur. Acad. Dermatol. Venereol. 36, 332\u2013350 (2022).","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"28563_CR29","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1111\/j.1472-8206.2007.00552.x","volume":"22","author":"A Bate","year":"2008","unstructured":"Bate, A., Lindquist, M. & Edwards, I. R. The application of knowledge discovery in databases to post-marketing drug safety: example of the WHO database. Fundam Clin. Pharmacol. 22, 127\u2013140 (2008).","journal-title":"Fundam Clin. Pharmacol."},{"key":"28563_CR30","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1016\/S0140-6736(00)02799-9","volume":"356","author":"IR Edwards","year":"2000","unstructured":"Edwards, I. R. & Aronson, J. K. Adverse drug reactions: definitions, diagnosis, and management. Lancet 356, 1255\u20131259 (2000).","journal-title":"Lancet"},{"key":"28563_CR31","doi-asserted-by":"publisher","first-page":"453","DOI":"10.2165\/00002018-200225060-00010","volume":"25","author":"ACG Egberts","year":"2002","unstructured":"Egberts, A. C. G. & Meyboom, R. H. B. Puijenbroek, E. P. Use of measures of disproportionality in pharmacovigilance: three Dutch examples. Drug Saf. 25, 453\u2013458 (2002). van.","journal-title":"Drug Saf."},{"key":"28563_CR32","doi-asserted-by":"crossref","unstructured":"Charles Dolladille & Basile Chretien. VigiBase Pharmacovigilance Database Toolbox. https:\/\/pharmacologie-caen.github.io\/vigicaen\/ at (2025).","DOI":"10.32614\/CRAN.package.vigicaen"},{"key":"28563_CR33","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-024-01423-7","author":"M Fusaroli","year":"2024","unstructured":"Fusaroli, M. et al. The reporting of A disproportionality analysis for drug safety signal detection using individual case safety reports in pharmacovigilance (READUS-PV): explanation and elaboration. Drug Saf. https:\/\/doi.org\/10.1007\/s40264-024-01423-7 (2024).","journal-title":"Drug Saf."},{"key":"28563_CR34","doi-asserted-by":"publisher","first-page":"4794","DOI":"10.1002\/cam4.5283","volume":"12","author":"D Lv","year":"2023","unstructured":"Lv, D. et al. Association between depression and anxiety status of breast cancer patients before adjuvant chemotherapy and chemotherapy-induced adverse events. Cancer Med. 12, 4794\u20134800 (2023).","journal-title":"Cancer Med."},{"key":"28563_CR35","doi-asserted-by":"publisher","first-page":"20015","DOI":"10.1002\/cam4.6556","volume":"12","author":"Z Peng","year":"2023","unstructured":"Peng, Z. et al. Depression and anxiety in cancer patient enrolled in clinical trials with serious adverse events. Cancer Med. 12, 20015\u201320026 (2023).","journal-title":"Cancer Med."},{"key":"28563_CR36","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1007\/s40264-016-0463-4","volume":"39","author":"G Durrieu","year":"2016","unstructured":"Durrieu, G. et al. Completeness of spontaneous adverse drug reaction reports sent by general practitioners to a regional pharmacovigilance centre: A descriptive study. Drug Saf. 39, 1189\u20131195 (2016).","journal-title":"Drug Saf."},{"key":"28563_CR37","doi-asserted-by":"publisher","first-page":"3754","DOI":"10.3390\/ijerph19073754","volume":"19","author":"MR Salvador","year":"2022","unstructured":"Salvador, M. R., Monteiro, C., Pereira, L. & Duarte, A. P. Quality of spontaneous reports of adverse drug reactions sent to a regional pharmacovigilance unit. Int. J. Environ. Res. Public. Health. 19, 3754 (2022).","journal-title":"Int. J. Environ. Res. Public. Health"},{"key":"28563_CR38","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/S0140-6736(08)60991-5","volume":"372","author":"V Strong","year":"2008","unstructured":"Strong, V. et al. Management of depression for people with cancer (SMaRT oncology 1): a randomised trial. Lancet 372, 40\u201348 (2008).","journal-title":"Lancet"},{"key":"28563_CR39","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1016\/j.jpain.2009.06.012","volume":"10","author":"A Latremoliere","year":"2009","unstructured":"Latremoliere, A. & Woolf, C. J. Central sensitization: A generator of pain hypersensitivity by central neural plasticity. J. Pain. 10, 895\u2013926 (2009).","journal-title":"J. Pain"},{"key":"28563_CR40","doi-asserted-by":"crossref","unstructured":"Sheng, J., Liu, S., Wang, Y., Cui, R. & Zhang, X. The Link between Depression and Chronic Pain: Neural Mechanisms in the Brain. Neural Plast 9724371 (2017). (2017).","DOI":"10.1155\/2017\/9724371"},{"key":"28563_CR41","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1097\/PSY.0000000000000089","volume":"76","author":"A Gupta","year":"2014","unstructured":"Gupta, A. et al. Early adverse life events and resting state neural networks in patients with chronic abdominal pain: evidence for sex differences. Psychosom. Med. 76, 404\u2013412 (2014).","journal-title":"Psychosom. Med."},{"key":"28563_CR42","doi-asserted-by":"publisher","first-page":"7","DOI":"10.5056\/jnm17137","volume":"24","author":"BGV Meerveld","year":"2018","unstructured":"Meerveld, B. G. V. & Johnson, A. C. Mechanisms of Stress-induced visceral pain. J. Neurogastroenterol Motil. 24, 7\u201318 (2018).","journal-title":"J. Neurogastroenterol Motil."},{"key":"28563_CR43","doi-asserted-by":"crossref","unstructured":"Fleming, M. A., Ehsan, L., Moore, S. R. & Levin, D. E. The Enteric Nervous System and Its Emerging Role as a Therapeutic Target. Gastroenterol Res Pract 8024171 (2020). (2020).","DOI":"10.20944\/preprints202006.0135.v1"},{"key":"28563_CR44","doi-asserted-by":"publisher","first-page":"20343","DOI":"10.1074\/jbc.M110.116988","volume":"285","author":"M Asim","year":"2010","unstructured":"Asim, M. et al. Helicobacter pylori induces ERK-dependent formation of a Phospho-c-Fos\u00b7c-Jun activator Protein-1 complex that causes apoptosis in macrophages. J. Biol. Chem. 285, 20343\u201320357 (2010).","journal-title":"J. Biol. Chem."},{"key":"28563_CR45","first-page":"3061","volume":"63","author":"K Laud","year":"2003","unstructured":"Laud, K. et al. BRAF as a melanoma susceptibility candidate gene? Cancer Res. 63, 3061\u20133065 (2003).","journal-title":"Cancer Res."},{"key":"28563_CR46","unstructured":"Corblin, M. L\u2019implication du microbiote intestinal dans l\u2019apparition des troubles d\u00e9pressifs\u2009=\u2009The involvement of the intestinal microbiota in the onset of depressive disorders. http:\/\/aurore.unilim.fr\/ori-oai-search\/notice\/view\/unilim-ori-111212 at (2020)."},{"key":"28563_CR47","doi-asserted-by":"publisher","first-page":"65","DOI":"10.3917\/psys.102.0065","volume":"30","author":"D Vust","year":"2010","unstructured":"Vust, D. Psychodermatologie et moi-peau. Psychoth\u00e9rapies 30, 65\u201374 (2010).","journal-title":"Psychoth\u00e9rapies"},{"key":"28563_CR48","doi-asserted-by":"publisher","unstructured":"Scutari, M., Kerob, D. & Salah, S. Inferring Skin-Brain-Skin Connections from Infodemiology Data using Dynamic Bayesian Networks. Preprint at (2024). https:\/\/doi.org\/10.48550\/arXiv.2405.06405","DOI":"10.48550\/arXiv.2405.06405"},{"key":"28563_CR49","doi-asserted-by":"publisher","first-page":"R101","DOI":"10.1186\/gb-2012-13-11-r101","volume":"13","author":"PLJM Zeeuwen","year":"2012","unstructured":"Zeeuwen, P. L. J. M. et al. Microbiome dynamics of human epidermis following skin barrier disruption. Genome Biol. 13, R101 (2012).","journal-title":"Genome Biol."},{"key":"28563_CR50","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1038\/jid.2010.278","volume":"131","author":"HD de Koning","year":"2011","unstructured":"de Koning, H. D. et al. Epidermal expression of host response genes upon skin barrier disruption in normal skin and uninvolved skin of psoriasis and atopic dermatitis patients. J. Invest. Dermatol. 131, 263\u2013266 (2011).","journal-title":"J. Invest. Dermatol."},{"key":"28563_CR51","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.3390\/ijms23031813","volume":"23","author":"YR Woo","year":"2022","unstructured":"Woo, Y. R., Cho, S. H., Lee, J. D. & Kim, H. S. The human microbiota and skin cancer. Int. J. Mol. Sci. 23, 1813 (2022).","journal-title":"Int. J. Mol. Sci."},{"key":"28563_CR52","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s40263-018-0490-z","volume":"32","author":"H Ghanean","year":"2018","unstructured":"Ghanean, H., Ceniti, A. K. & Kennedy, S. H. Fatigue in patients with major depressive disorder: Prevalence, burden and Pharmacological approaches to management. CNS Drugs. 32, 65\u201374 (2018).","journal-title":"CNS Drugs"},{"key":"28563_CR53","first-page":"564","volume":"30","author":"M Maes","year":"2009","unstructured":"Maes, M. Functional\u2019 or \u2018psychosomatic\u2019 symptoms, e.g. A flu-like malaise, aches and pain and fatigue, are major features of major and in particular of melancholic depression. Neuro Endocrinol. Lett. 30, 564\u2013573 (2009).","journal-title":"Neuro Endocrinol. Lett."},{"key":"28563_CR54","doi-asserted-by":"publisher","first-page":"20647","DOI":"10.1038\/srep20647","volume":"6","author":"MC Lu","year":"2016","unstructured":"Lu, M. C. et al. Bidirectional associations between rheumatoid arthritis and depression: a nationwide longitudinal study. Sci. Rep. 6, 20647 (2016).","journal-title":"Sci. Rep."},{"key":"28563_CR55","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1007\/s11764-013-0286-6","volume":"7","author":"F Mols","year":"2013","unstructured":"Mols, F., Husson, O., Roukema, J. A. & van de Poll-Franse, L. V. Depressive symptoms are a risk factor for all-cause mortality: results from a prospective population-based study among 3,080 cancer survivors from the PROFILES registry. J. Cancer Surviv. 7, 484\u2013492 (2013).","journal-title":"J. Cancer Surviv"},{"key":"28563_CR56","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1245\/s10434-012-2793-5","volume":"20","author":"O Arrieta","year":"2013","unstructured":"Arrieta, O. et al. Association of depression and anxiety on quality of life, treatment adherence, and prognosis in patients with advanced non-small cell lung cancer. Ann. Surg. Oncol. 20, 1941\u20131948 (2013).","journal-title":"Ann. Surg. Oncol."},{"key":"28563_CR57","doi-asserted-by":"publisher","first-page":"110169","DOI":"10.1016\/j.jpsychores.2020.110169","volume":"136","author":"AA Cohee","year":"2020","unstructured":"Cohee, A. A. et al. Predictors of depression outcomes in adults with cancer: A 12-Month longitudinal study. J. Psychosom. Res. 136, 110169 (2020).","journal-title":"J. Psychosom. Res."},{"key":"28563_CR58","doi-asserted-by":"publisher","first-page":"3188","DOI":"10.1038\/s41598-024-53212-y","volume":"14","author":"V Velasco-Durantez","year":"2024","unstructured":"Velasco-Durantez, V. et al. Prospective study of predictors for anxiety, depression, and somatization in a sample of 1807 cancer patients. Sci. Rep. 14, 3188 (2024).","journal-title":"Sci. Rep."},{"key":"28563_CR59","doi-asserted-by":"crossref","unstructured":"Grassi, L. et al. Anxiety and depression in adult cancer patients: ESMO clinical practice Guideline\u2020. ESMO Open 8, (2023), 101155.","DOI":"10.1016\/j.esmoop.2023.101155"},{"key":"28563_CR60","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s40035-020-00221-2","volume":"9","author":"HS Kwon","year":"2020","unstructured":"Kwon, H. S. & Koh, S. H. Neuroinflammation in neurodegenerative disorders: the roles of microglia and astrocytes. Translational Neurodegeneration. 9, 42 (2020).","journal-title":"Translational Neurodegeneration"},{"key":"28563_CR61","doi-asserted-by":"publisher","first-page":"1060948","DOI":"10.3389\/fpsyt.2022.1060948","volume":"13","author":"Z Freyberg","year":"2022","unstructured":"Freyberg, Z., Leboyer, M., Penninx, B. W. J. H. & Logan, R. W. Editorial: Neuroinflammation, metabolism, and psychiatric disorders. Front. Psychiatry. 13, 1060948 (2022).","journal-title":"Front. Psychiatry"},{"key":"28563_CR62","doi-asserted-by":"publisher","first-page":"980197","DOI":"10.3389\/fonc.2022.980197","volume":"12","author":"J Oh","year":"2022","unstructured":"Oh, J. et al. Risk of developing depression from endocrine treatment: A nationwide cohort study of women administered treatment for breast cancer in South Korea. Front. Oncol. 12, 980197 (2022).","journal-title":"Front. Oncol."},{"key":"28563_CR63","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.therap.2019.01.006","volume":"74","author":"JL Faillie","year":"2019","unstructured":"Faillie, J. L. Case-non-case studies: Principle, methods, bias and interpretation. Therapie 74, 225\u2013232 (2019).","journal-title":"Therapie"},{"key":"28563_CR64","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1111\/j.1365-2125.2011.04037.x","volume":"72","author":"JL Montastruc","year":"2011","unstructured":"Montastruc, J. L., Sommet, A., Bagheri, H. & Lapeyre-Mestre, M. Benefits and strengths of the disproportionality analysis for identification of adverse drug reactions in a pharmacovigilance database. Br. J. Clin. Pharmacol. 72, 905\u2013908 (2011).","journal-title":"Br. J. Clin. Pharmacol."},{"key":"28563_CR65","doi-asserted-by":"publisher","first-page":"453","DOI":"10.2165\/00002018-200225060-00010","volume":"25","author":"ACG Egberts","year":"2002","unstructured":"Egberts, A. C. G. & Meyboom, R. H. B. Puijenbroek, E. P. Use of measures of disproportionality in pharmacovigilance. Drug-Safety 25, 453\u2013458 (2002). van.","journal-title":"Drug-Safety"},{"key":"28563_CR66","doi-asserted-by":"publisher","unstructured":"Garbe, E. & Suissa, S. in Handbook of Epidemiology (eds Ahrens, W. & Pigeot, I.) 1875\u20131925Springer New York, (2014). https:\/\/doi.org\/10.1007\/978-0-387-09834-0_31","DOI":"10.1007\/978-0-387-09834-0_31"},{"key":"28563_CR67","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1080\/14740338.2024.2383707","volume":"24","author":"JM Quik","year":"2025","unstructured":"Quik, J. M. et al. The burden of adverse drug reactions reported by patients in the Dutch ADR monitor: a proof of concept. Expert Opin. Drug Saf. 24, 1023\u20131033 (2025).","journal-title":"Expert Opin. Drug Saf."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-28563-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-28563-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-28563-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T17:02:20Z","timestamp":1777136540000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-28563-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,16]]},"references-count":67,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["28563"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-28563-9","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,16]]},"assertion":[{"value":"18 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable, as this study does not include identifiable individual data.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"This study is based on anonymized pharmacovigilance data from VigiBase\n                      \u00ae\n                      . Since the data do not contain personally identifiable information and were collected for regulatory purposes, ethical approval from an Institutional Review Board (IRB) was not required, in accordance with local and international ethical guidelines. This study was conducted in compliance with the Declaration of Helsinki.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"45751"}}